Sugarmade (SGMD) Secures Cultivation Facility, Continues

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
395
Sugarmade (SGMD) Secures Cultivation Facility, Continues Impressive Upward Trajectory

- Secures a 5,000-square-foot facility with potential for 250 pounds output per month
- Seeing month-over-month growth with BudCars across all metrics
- Submitted application to expand BudCars into cannabis cultivation

Sugarmade (OTCQB: SGMD), a product and branding marketing company investing in operations and technologies with disruptive potential, recently secured a 5,000-square-foot indoor premium cannabis cultivation facility. Located near its Sacramento Budcars Cannabis Delivery Service hub, this new facility has production potential for as much as 250 pounds of premium dried cannabis flower per month. Based on current local averages the facility has the potential of producing as much a $1.6 million in new BudCars sales per month. As a vertical farm-to-door operation the company would also experience significant savings in cost.

BudCars is a top-shelf cannabis retail business that offers same-day delivery of top-quality product. Customers can choose from edibles, flower, pre-rolls, vapes, tinctures and concentrate from dozens of premium brands. Once the selection is made and the purchase completed online. BudCars delivers to a customer’s front door, same day.

SGMD acquired the Sacramento-based BudCars in February 2020. Since that time, the company has expanded the service geographically; it currently reaches into the communities of Granite Bay, Folsom, Arden Arcade, Carmichael, Citrus Heights, Orangevale and Roseville/Rocklin (http://nnw.fm/iDrS9). Sugarmade has seen dramatic growth and is working on expanding even further into Southern California.

“The growth has been so dramatic that we have had to drastically revise our expectations to the upside, which demands expansion, both in terms of staff and fleet in Sacramento, and in terms of regional expansion into Southern California,” said Sugarmade CEO Jimmy Chan. “As a result, we are acquiring two distribution hub locations in the LA area with cannabis licenses included so we can hit the ground running” (http://nnw.fm/Uy8MC).

That growth hasn’t slowed down as the company continues to experience record growth in every metric. In June BudCars achieved total sales of $502,903, representing a 30% month-over-month growth for three consecutive months. The company is seeing an average daily sales increase of 41% month over month along with an average customer order increase of 2% per order (http://nnw.fm/d4OcD).

“Our pricing improved. Our average order improved. We did more business with more people and booked a significant jump in gross profits while holding our 47% gross margin level as volume increased,” Chan reported (http://nnw.fm/wDg8n). “We look forward to continued breakout growth in July.”

SGMD has submitted an application to expand into cannabis cultivation. The company is looking to strategically grow BudCars through verticalization. Through the expansion into cultivation, once approved by the California Bureau of Cannabis Control, the move would connect the dots and form a solid product and supply line from farm to delivery that would further cut costs and increase the profit margins (http://nnw.fm/rmz2R).

For more information, visit the company’s website at www.Sugarmade.com.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Sugarmade Inc. (SGMD) Stock Research Links

SGMD Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Huawei Introduces Innovative Wearables for Enhanced Connectivity

Updated Category News Views 293

Huawei Unveils Next-Generation Wearables and Tablets At a much-anticipated event, Huawei Consumer Business Group (CBG) revealed a thrilling array of new products. This launch showcased a strong emphasis on trendy wearables and sophisticated tablets, highlighting the brand's dedication to innovation and a user-friendly design. Chic Wearables for Style and Utility Among the...

Continue Reading
Investigating Barnes & Noble Education: Shareholder Rights Explained

Updated Category News Views 155

Understanding the Investigation of Barnes & Noble Education In a proactive move for investors, the law firm Bragar Eagel & Squire, P.C. is currently investigating Barnes & Noble Education, Inc. (BNED). This investigation aims to determine whether the company potentially breached federal securities laws or engaged in unlawful business practices that could lead to...

Continue Reading
Bailey Kennedy Achieves Landmark Legal Win for Talisman Group

Updated Category News Views 171

Bailey Kennedy Achieves Legal Victory for Talisman Group Judge Rules LNW Violated Talisman's Distribution Agreement by Marketing Competing Game In a significant legal development, Bailey Kennedy, LLP has successfully represented The Talisman Group, LLC, the innovative minds behind EZ Baccarat. The firm has recently triumphed in a legal dispute against LNW Gaming, Inc.,...

Continue Reading
Join the Class Action Lawsuit Against Ardelyx, Inc. Now

Updated Category News Views 49

Join the Class Action Lawsuit Against Ardelyx, Inc. Attention Ardelyx, Inc. investors! There's an important class action lawsuit underway, and this is your opportunity to get involved. Bronstein, Gewirtz & Grossman, LLC, a respected law firm known for its dedication to investor advocacy, has announced a class action case involving Ardelyx, Inc. (NASDAQ: ARDX) and certain...

Continue Reading
Aileron Therapeutics Unveils Q3 2024 Financial Performance

Updated Category News Views 97

Aileron Therapeutics Reports Impressive Q3 2024 Financial Results Aileron Therapeutics, Inc. (NASDAQ: ALRN), a biopharmaceutical company committed to developing innovative medicines for orphan pulmonary diseases, has recently showcased significant progress with their third-quarter financial results. This quarter has been marked by promising advancements in clinical trials...

Continue Reading